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that an Sua-related gene LRP2 is not involved in gout 
susceptibility.
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hyperlipidemia · urate exporter · Low-density lipoprotein 
receptor (LDLR) · LDLR gene family
Introduction
Gout is a common disease as a consequence of hyperurice-
mia. a recent genome-wide association study (GWaS) 
[1] with 8,868 Japanese revealed the association between 
serum uric acid (Sua) levels and rs2544390, which is a 
single nucleotide polymorphism (SnP) in low-density lipo-
protein-related protein 2 (LRP2, also known as Megalin). 
LRP2 is a member of the low-density lipoprotein receptor 
[LDLR (mIm606945)] gene family, and two SnPs of LRP2, 
rs2229268 and rs3755166, are also found to have asso-
ciations with dyslipidemia [2] and alzheimer’s disease [3], 
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respectively. In this study, we investigated the association 




all procedures were carried out in accordance with the stand-
ards of the institutional ethical committees involved in this 
project and the Declaration of helsinki. Written informed 
consent was obtained from each subject participating in this 
study. as gout cases, 741 Japanese male individuals were 
collected from the outpatients of the gout clinics in either 
Jikei university hospital (tokyo, Japan) or midorigaoka 
hospital (Osaka, Japan). all of them were clinically diag-
nosed with primary gout according to the criteria estab-
lished by the american College of Rheumatology [4]. as a 
control group, 1,302 Japanese male individuals with nor-
mal Sua (≤7.0 mg/dl) without gout history were collected 
from the Japan multi-Institutional Collaborative Cohort 
Study (J-mICC Study) [5]. the mean age and body-mass 
index with standard deviation are 55.0 ± 13.2 years old and 
24.6 ± 3.5 kg/m2 for cases, respectively, and 52.7 ± 8.4 years 
old and 23.2 ± 2.8 kg/m2 for controls, respectively.
Genetic analysis and statistical analysis
Genomic Dna was extracted from whole peripheral 
blood cells [6]. Genotyping of rs2544390, rs2229268, and 
rs3755166 in LRP2 gene was performed by an allelic dis-
crimination assay (Custom taqman mGB, applied Bio-
systems) with a LightCycler 480 (Roche Diagnostics) [7]. 
to confirm their genotypes, more than 25 samples were 
subjected to direct sequencing with the following primers: 
for rs2544390, forward 5′-CtGtCtGaGaCCatGaCaC 
aG-3′ and reverse, 5′-CCtCaCCtGtCattGtCttG-3′; 
for 2229268, forward 5′-tCCGttCaaCtttCaGaCaG-3′ 
and reverse 5′-ttCCCaaCtttCtCaGGttaC-3′; for 
3755166, forward 5′-GtGtaaGGCCaCttGtGC-3′ and 
reverse 5′-GaaatGGaCGaGGaGGaaaG-3′. Dna 
sequencing analysis was performed with a 3130xl Genetic 
analyzer (applied Biosystems) [8].
the software R (version 3.0.2) (http://www.r-project.org/) 
with package GenaBEL was used for the calculation of link-
age disequilibrium (r2). For the calculations in the statistical 
analyses, SPSS v.17.0J (IBm Japan Inc., tokyo, Japan) was 
used. the χ2 test was used for association analysis.
Results
table 1 shows the alleles of LRP2 variants, rs2544390, 
rs2229268, and rs3755166, for 2,043 Japanese partici-
pants (741 gout cases and 1,302 controls). the call rates 
for rs2544390, rs3755166, and rs2229268 were 98.2, 98.1, 
and 99.5 %, respectively. P values for hardy–Weinberg 
equilibrium of these SnPs were 0.039, 0.095, and 0.134. 
P values that suggested mistyping were not obtained. the 
minor allele frequencies (maFs) for the three LRP2 variants 
were more than 0.27 in both case and control groups, indi-
cating these SnPs are very common in both these groups. 
no strong linkage disequilibrium was observed between 
these three SnPs (r2 = 0.0014 between rs2544390 and 
rs2229268, r2 = 0.0013 between rs2229268 and rs3755166, 
r2 = 0.15 between rs3755166 and rs2544390, respectively), 
showing that these SnPs are independent of each other.
For all gout cases, the association analyses of the three 
LRP2 variants, rs2544390, rs2229268, and rs3755166, 
showed no association with gout (table 1).
Discussion
Our study demonstrated that the three LRP2 variants, 
rs2544390, rs2229268, and rs3755166, had no association 
with gout.
Table 1  association analysis of LRP2 variants, rs2544390, rs2229268, and rs3755166 in gout patients
MAF minor allele frequency, OR odds ratio, CI confidence interval
a
 SnP positions are based on nCBI human genome reference sequence build 37.5. LRP2 is located on chromosome 2q31.1
b
 the major allele was referred to as allele 1 and the minor allele as 2. allele 1 is C and allele 2 is t in rs2544390. allele 1 is a and allele 2 is G 
in rs2229268. allele 1 is a and allele 2 is G in rs3755166
Chromosomal positionsa (bp) allelesb P value OR 95 % CI
Case Control
1 2 maF 1 2 maF
rs2544390 170204846 747 717 0.490 1,314 1,236 0.485 0.758 1.020 0.897–1.160
rs2229268 170025083 1,051 423 0.287 1,829 705 0.278 0.552 1.044 0.906–1.204
rs3755166 170219881 702 778 0.474 1,277 1,307 0.494 0.223 1.083 0.953–1.231
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Recent GWaS of Sua [9, 10] identified several genes 
including GLUT9/SLC2A9 and ABCG2/BCRP, which have 
been revealed to have associations with urate disorders such 
as renal hypouricemia [11, 12] and gout [13, 14]. Recent 
reports also show the significance of transporter genes such 
as ABCG2 [15, 16], NPT1/SLC17A1 [17], MCT9/SLC16A9 
[18], and OAT4/SLC22A11 [19], for the pathogenesis 
of gout. LRP2 was first reported to have the association 
with Sua in the GWaS by Kamatani et al. [1]. although 
we found no studies reporting that LRP2 transports urate, 
LRP2 variants could have an association with gout risks 
because gout is a consequence of hyperuricemia. moreover, 
it is also demonstrated that LRP2 is a multi-ligand recep-
tor and is expressed in various tissues, mainly in the kid-
ney, especially in glomeruli and proximal tubular cells. as 
LRP2 has a role of renal reabsorption for its ligands such as 
insulin [20], LRP2 variants could have an association with 
Sua variation with increasing insulin resistance.
LRP2 is originally found as a member of the low-den-
sity lipoprotein (LDL) receptor family and has been sug-
gested to mediate endocytosis of LDL. Indeed, mii et al. 
[2] reported that one variant of LRP2, rs2229268, has an 
association with serum LDL levels in humans, indicating 
the direct association between LRP2 and LDL. Since dys-
lipidemia is known as a risk to increase the insulin resist-
ance, rs2229268 seems to have an association with Sua 
variation. Otherwise, LRP2 could be associated with Sua 
variation through the endocytosis of urate-binding proteins.
Interestingly, Wang et al. [3] previously reported the 
association between rs3755166 in LRP2 and alzheimer’s 
disease in a Chinese population. LRP2, whose ligand apoE 
[21] is known for the risk of alzheimer’s disease [22, 23], 
is expressed in brain and facilitates the clearance of the 
aβ peptide, that is, the cause of alzheimer’s disease [24]. 
together with the fact that urate has anti-oxidant effects, 
LRP2 variants carrying the risk of alzheimer’s disease 
might have an association with Sua variation.
however, the present study first revealed that the com-
mon variants of LRP2 have no association with gout suscep-
tibility. although LRP2 was first reported to have an asso-
ciation with Sua in Japanese population [1], there are no 
replication studies indicating an association between LRP2 
and Sua in other ancestry such as a European population. 
It is possible that the present study failed to show these 
associations due to the limited sample (2,043 individuals). 
although further studies of LRP2 are necessary to reveal the 
relationship between LRP2 variants and gout, our study at 
least revealed that LRP2 is not a strong genetic risk for gout.
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